High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder (HDQ)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia Schizoaffective Disorder |
Drug: quetiapine |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder |
- To see if mean extrapyramidal symptoms measure will change significantly from baseline to endpoint for the whole group and if the mean change in EPS measure is significantly different between quetiapine 1200mg daily group and quetiapine 600mg daily group [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
- To see if treatment with quetiapine 1200 mg per day will improve total PANSS more robustly than quetiapine 600 mg per day [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | December 2004 |
| Estimated Study Completion Date: | December 2012 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 600 mg/day quetiapine (Group B) |
Drug: quetiapine
Participant will receive 600 mg/day of quetiapine for 8 weeks.
Other Name: Seroquel
|
| Experimental: 1200 mg/day quetiapine (Group A) |
Drug: quetiapine
Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
Other Name: Seroquel
|
Detailed Description:
The study will be conducted at two sites: Manhattan Psychiatric Center (MPC), and the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research/Rockland Psychiatric Center (NKI). A total of 60 patients will be enrolled, 30 at each location. After a screening period of 1 week, all patients will be entering an open label, four-week quetiapine treatment period (run-in phase), during which quetiapine will be titrated to 600 mg PO daily and other adjunctive antipsychotics will be gradually tapered and discontinued. Other concomitant medications such as mood stabilizers will be maintained, if their dose has been stable for the preceding 2 months. Patients not responding to quetiapine treatment at 600 mg PO (defined as reduction of < 15% change in Positive and Negative Syndrome Scale (PANSS) total score between start of run-in to end of week 4) during the run-in phase, will be eligible to enter the double blind phase. Study baseline will be Day 7 of Week 4 of the run-in phase. Patients qualifying for the double-blind phase will be randomly assigned to either high dose 1200 mg quetiapine daily (Group A) or to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double blind fashion for 8 weeks (Week 1 through Week 8 of double blind phase). Measures of extra-pyramidal side effects, psychopathology, and safety will be conducted throughout the trial.
Eligibility| Ages Eligible for Study: | 18 Years to 64 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- DSM-IV criteria for chronic schizophrenia or schizoaffective disorder
- Sub-optimal treatment-response
- Total score > 60 on the Positive and Negative Syndrome Scale (PANSS) at baseline of run-in phase and again at baseline of double blind phase
- Age 18-64 years old
- Signed informed consent
- Patient is in good general medical health
Exclusion criteria:
- History of failure to respond to 400 mg/day or more of clozapine for 8 contiguous weeks
- History of failure to respond to quetiapine treatment at dosages > 1200 mg daily for 6 contiguous weeks
- History of quetiapine intolerance (e.g., clinically significant leukopenia or agranulocytosis, or severe dystonic reactions)
- Significant recent history of violence or suicidal activity, which required > 4 episodes of PRN anti-agitation medication per week
- Mental retardation
- Depot antipsychotic within 30 days before randomization
- Significant medical illness requiring frequent dose adjustment or medication changes
Clozapine non-responders are explicitly excluded, as they would be unlikely to show a response in this study.
Contacts and Locations| United States, New York | |
| Manhattan Psychiatric Center | |
| New York, New York, United States, 10035 | |
| Nathan Kline Institute for Psychiatric Research | |
| Orangeburg, New York, United States, 10962 | |
| Principal Investigator: | Jean-Pierre Lindenmayer, MD | Manhattan Psychiatric Center |
| Principal Investigator: | Leslie Citrome, MD | Nathan Kline Institute for Psychiatric Research |
More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jean-Pierre Lindenmayer, Manhattan Psychiatric Center |
| ClinicalTrials.gov Identifier: | NCT00297947 History of Changes |
| Other Study ID Numbers: | IRUSQUET0348 |
| Study First Received: | February 27, 2006 |
| Last Updated: | July 28, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Manhattan Psychiatric Center:
|
schizophrenia quetiapine schizoaffective disorder |
Additional relevant MeSH terms:
|
Psychotic Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Quetiapine Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 19, 2013